至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Systematic Synthesis and Binding Study of HIV V3 Glycopeptides Reveal the Fine Epitopes of Several Broadly Neutralizing Antibodies.

ACS Chem. Biol.. 2017-06; 
OrwenyoJared, CaiHui, GiddensJohn, AminMohammed N, ToonstraChristian, WangLa
Products/Services Used Details Operation
Biochemicals Page 1. Open Citation: J Med Discov (2017); 2(4):jmd17039; DOI:10.24262/jmd.2.4. 17039 * Correspondence: Shiqiang Lu, PhD, Genscript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854, USA. Email: shiqianglu@genscript Get A Quote

摘要

A class of new glycan-reactive broadly neutralizing antibodies represented by PGT121, 10-1074, and PGT128 has recently been discovered that targets specific N-glycans and the peptide region around the V3 domain. However, the glycan specificity and fine epitopes of these bNAbs remain to be further defined. We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites. Antibody binding studies revealed that both the nature and site of glycosylation in the context of the V3 domain were critical for high-affinity binding. It was found that antibody PGT128 exhibited specificity for high-manno... More

关键词